乳腺癌中的表皮生长因子受体（ErbB/HER）家族——我们探索得越多，了解得就越多。 - Suppr | 超能文献

ErbB/HER receptor family in breast cancer--the more we search the more we learn.

作者信息

Karamouzis M V, Konstantinopoulos P A, Papavassiliou A G

出版信息

Ann Oncol. 2008 May;19(5):1020-1. doi: 10.1093/annonc/mdn061. Epub 2008 Mar 19.

DOI:10.1093/annonc/mdn061

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

ErbB/HER receptor family in breast cancer--the more we search the more we learn.乳腺癌中的表皮生长因子受体（ErbB/HER）家族——我们探索得越多，了解得就越多。

Ann Oncol. 2008 May;19(5):1020-1. doi: 10.1093/annonc/mdn061. Epub 2008 Mar 19.

2

Update on HER-kinase-directed therapy in prostate cancer.前列腺癌中HER激酶导向治疗的最新进展。

Clin Adv Hematol Oncol. 2004 Jan;2(1):53-6, 64.

3

[The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm].[肿瘤学中靶向治疗的应用及其对临床试验设计的影响：以表皮生长因子受体1和2为例]

Med Clin (Barc). 2013 Aug 17;141(4):176-80. doi: 10.1016/j.medcli.2013.04.008. Epub 2013 Jun 27.

4

Anti-epidermal growth factor receptor strategies for advanced breast cancer.晚期乳腺癌的抗表皮生长因子受体策略

Cancer Invest. 2008 Oct;26(8):757-68. doi: 10.1080/07357900801971040.

5

The FUTURE of ErbB-1 and ErbB-2 pathway inhibition in breast cancer: targeting multiple receptors.表皮生长因子受体1和表皮生长因子受体2通路抑制在乳腺癌治疗中的未来：靶向多种受体

Oncologist. 2004;9 Suppl 3:1-3. doi: 10.1634/theoncologist.9-suppl_3-1.

6

Ten years of HER2-directed therapy: still questions after all these years.十年的HER2靶向治疗：多年之后仍有诸多问题。

Breast Cancer Res Treat. 2009 Jan;113(2):207-9. doi: 10.1007/s10549-008-0041-2. Epub 2008 May 8.

7

Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.用于治疗肺癌和乳腺癌的不可逆多靶点表皮生长因子受体（ErbB）家族抑制剂

Curr Cancer Drug Targets. 2015;14(9):775-93. doi: 10.2174/1568009614666141111104643.

8

The role of ErbB inhibitors in trastuzumab resistance.表皮生长因子受体（ErbB）抑制剂在曲妥珠单抗耐药中的作用。

Oncologist. 2004;9 Suppl 3:16-9. doi: 10.1634/theoncologist.9-suppl_3-16.

9

An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.一种对具有ERBB配体过表达的耐药HER2+乳腺癌具有高活性的ERBB1-3中和抗体混合物。

J Natl Cancer Inst. 2017 Nov 1;109(11). doi: 10.1093/jnci/djx065.

10

Trastuzumab-treated advanced breast cancer patients and brain metastases: just a little alert.

Ann Oncol. 2008 Jan;19(1):191. doi: 10.1093/annonc/mdm530.

引用本文的文献

1

Superior efficacy of the antifungal agent ciclopirox olamine over gemcitabine in pancreatic cancer models.在胰腺癌模型中，抗真菌药环吡酮胺比吉西他滨具有更高的疗效。

Oncotarget. 2017 Dec 8;9(12):10360-10374. doi: 10.18632/oncotarget.23164. eCollection 2018 Feb 13.

2

Plasma biomarker profiles differ depending on breast cancer subtype but RANTES is consistently increased.血浆生物标志物谱因乳腺癌亚型而异，但 RANTES 始终增加。

Cancer Epidemiol Biomarkers Prev. 2011 Jul;20(7):1543-51. doi: 10.1158/1055-9965.EPI-10-1248. Epub 2011 May 17.